Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 178

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 178
---
 Agreement) for each calendar quarter (commencing with the calendar quarter beginning January 1, 2025) promptly, but in any event no later than 60 calendar days after the
end of each calendar quarter.

The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the
Gloperba-Elyxyb RPA Purchasers of all payments of the Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Payment Term.

113

Royalty Security Agreement

Pursuant to the terms of the Gloperba-Elyxyb Royalty Purchase Agreement, we entered into the Gloperba-Elyxyb Royalty Security Agreement.

Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma’s due performance and payment under the
Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered
Products.

Subordination Agreement

In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, we entered into the
Gloperba-Elyxyb Subordination Agreement, by and among us, Scilex Pharma, the Gloperba-Elyxyb RPA Purchasers and the Note Agent. Pursuant to the Gloperba-Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and
indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by first priority liens on the Gloperba-Elyxyb Royalty Collateral and the Note Agent’s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a
second priority lien.

Amendment No. 1 to ZTlido Royalty Purchase Agreement

On February 28, 2025, we and Scilex Pharma entered into the ZTlido Royalty Amendment with the purchasers under the ZTlido Royalty Purchase
Agreement. Pursuant to the ZTlido Royalty Amendment, we and Scilex Pharma may assign our respective rights or delegate our respective obligations under the ZTlido Royalty Purchase Agreement without the prior written consent of the Purchasers if we
receive a commitment,